View Future GrowthChemPartner PharmaTechLtd 과거 순이익 실적과거 기준 점검 0/6ChemPartner PharmaTechLtd 의 수입은 연평균 -23.1%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 5%의 비율로 감소했습니다. 매출은 연평균 11.6%의 비율로 감소해 왔습니다.핵심 정보-23.05%순이익 성장률-23.26%주당순이익(EPS) 성장률Biotechs 산업 성장률11.29%매출 성장률-11.59%자기자본이익률-0.85%순이익률-1.00%다음 순이익 업데이트29 Aug 2026최근 과거 실적 업데이트공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025공고 • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jul 15Now 41% overvaluedOver the last 90 days, the stock has fallen 9.0% to CN¥10.39. The fair value is estimated to be CN¥7.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026Buy Or Sell Opportunity • Jun 29Now 36% overvaluedOver the last 90 days, the stock has fallen 4.7% to CN¥9.86. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025공고 • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025공고 • May 22Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd.Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. agreed to acquire 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. for approximately CNY 130 million on March 31, 2025. The consideration consist of CNY 5.064 per ChemPartner PharmaTech Co.,Ltd. share. Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. on May 20, 2025.공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time.공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025공고 • Nov 16ChemPartner PharmaTech Co.,Ltd. Approves the Election of DirectorsChemPartner PharmaTech Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 14 November 2024, during which the following proposal(s) was/were approved the election of Chen Wanglong as non-independent director and Zhang Xuemei as independent director.공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024Reported Earnings • Aug 30Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)Second quarter 2024 results: CN¥0.076 loss per share (down from CN¥0.011 profit in 2Q 2023). Revenue: CN¥230.6m (down 20% from 2Q 2023). Net loss: CN¥37.4m (down CN¥44.2m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.공고 • Jun 29ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024공고 • Apr 28Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China Agenda: To consider 2023 work report of the board of directors; to consider 2023 annual accounts report; to consider 2023 annual report and its summary; to consider 2023 profit distribution plan; to consider Application for comprehensive credit line to banks and other financial institutions and provision of guarantee; to consider Shareholder return plan for the next three years from 2024 to 2026; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; to consider Change of the Company's business scope and amendments to the Company's articles of association; to consider 2023 work report of the supervisory committee; and to consider other business matters.Reported Earnings • Apr 27First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)First quarter 2024 results: CN¥0.051 loss per share (improved from CN¥0.057 loss in 1Q 2023). Revenue: CN¥234.6m (down 13% from 1Q 2023). Net loss: CN¥25.5m (loss narrowed 11% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).공고 • Mar 30Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024공고 • Dec 30Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024Reported Earnings • Oct 25Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)Third quarter 2023 results: CN¥0.048 loss per share (down from CN¥0.13 profit in 3Q 2022). Revenue: CN¥288.7m (down 16% from 3Q 2022). Net loss: CN¥19.4m (down 129% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.011 (down from CN¥1.90 in 2Q 2022). Revenue: CN¥288.8m (down 3.9% from 2Q 2022). Net income: CN¥6.79m (down 99% from 2Q 2022). Profit margin: 2.4% (down from 315% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years.New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 58% over the past three years.Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)First quarter 2023 results: CN¥0.057 loss per share (down from CN¥0.019 profit in 1Q 2022). Revenue: CN¥268.7m (down 31% from 1Q 2022). Net loss: CN¥28.6m (down 402% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Jiahui Qi is the most experienced director on the board, commencing their role in 2018. Independent Director Ji Guo Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2021). Revenue: CN¥345.3m (down 17% from 3Q 2021). Net income: CN¥66.8m (up CN¥57.1m from 3Q 2021). Profit margin: 19% (up from 2.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)Second quarter 2022 results: EPS: CN¥1.90 (up from CN¥0.007 in 2Q 2021). Revenue: CN¥300.6m (down 34% from 2Q 2021). Net income: CN¥947.1m (up CN¥943.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.019 (up from CN¥0.003 in 1Q 2021). Revenue: CN¥386.3m (flat on 1Q 2021). Net income: CN¥9.47m (up 480% from 1Q 2021). Profit margin: 2.5% (up from 0.4% in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Member of the Supervisory Board Hai Zhang was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to CN¥12.10, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 44x in the Biotechs industry in China. Total loss to shareholders of 22% over the past three years.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥455.7m (up 16% from 2Q 2020). Net income: CN¥3.51m (down 94% from 2Q 2020). Profit margin: 0.8% (down from 14% in 2Q 2020).Valuation Update With 7 Day Price Move • May 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥16.39, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 41% over the past year.Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥389.7m (up 40% from 1Q 2020). Net income: CN¥1.63m (up CN¥15.8m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.Is New 90 Day High Low • Mar 16New 90-day low: CN¥12.64The company is down 27% from a price of CN¥17.30 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Lagged the Biotechs industry, which is down 6.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: CN¥12.66The company is down 36% from its price of CN¥19.93 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥14.46, the stock is trading at a trailing P/E ratio of 51.2x, down from the previous P/E ratio of 60.5x. This compares to an average P/E of 63x in the Biotechs industry in China. Total returns to shareholders over the past year are 10%.Is New 90 Day High Low • Dec 24New 90-day low: CN¥14.46The company is down 31% from its price of CN¥20.99 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.Is New 90 Day High Low • Nov 12New 90-day low: CN¥18.29The company is down 4.0% from its price of CN¥19.06 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.18 per share.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 8.5% from the prior year. Total revenue was CN¥1.44b over the last 12 months, up 8.5% from the prior year.매출 및 비용 세부 내역ChemPartner PharmaTechLtd가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XSEC:300149 매출, 비용 및 순이익 (CNY Millions)날짜매출순이익일반관리비연구개발비31 Mar 261,140-112526331 Dec 251,135132546030 Sep 251,069-1582755630 Jun 251,039-1382425231 Mar 25997-1942475531 Dec 24970-2262356030 Sep 241,011-9472356430 Jun 241,046-9582547231 Mar 241,104-9142417331 Dec 231,138-9172617730 Sep 231,141-6762317130 Jun 231,197-6002547231 Mar 231,2093413018501 Jan 231,3273793239230 Sep 221,46160637011430 Jun 221,53254937712431 Mar 221,687-39435412801 Jan 221,691-40233712530 Sep 211,6748630511730 Jun 211,65711928610931 Mar 211,5931702948831 Dec 201,4821552857230 Sep 201,4431413141930 Jun 201,383131319831 Mar 201,309993091031 Dec 191,3281393041130 Sep 191,3301302975030 Jun 191,3521562854631 Mar 191,2151762483431 Dec 189971612102730 Sep 187011201382030 Jun 1840979842231 Mar 1830356671831 Dec 1727558571530 Sep 1726461551030 Jun 172636657031 Mar 172566257031 Dec 162596557030 Sep 162525860030 Jun 162746671031 Mar 163026379031 Dec 153195988030 Sep 1531862930양질의 수익: 300149 은(는) 현재 수익성이 없습니다.이익 마진 증가: 300149는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 300149은 수익성이 없으며 지난 5년 동안 손실이 연평균 23.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 300149의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 300149은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(-6.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 300149는 현재 수익성이 없으므로 자본 수익률이 음수(-0.85%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/20 14:39종가2026/07/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ChemPartner PharmaTech Co.,Ltd.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullCMB International Securities LimitedXiao Bao LiuEverbright Securities Co. Ltd.Yun ZHANGHuatai Research
공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
공고 • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
Buy Or Sell Opportunity • Jul 15Now 41% overvaluedOver the last 90 days, the stock has fallen 9.0% to CN¥10.39. The fair value is estimated to be CN¥7.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
공고 • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
Buy Or Sell Opportunity • Jun 29Now 36% overvaluedOver the last 90 days, the stock has fallen 4.7% to CN¥9.86. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China
공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
공고 • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
공고 • May 22Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd.Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. agreed to acquire 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. for approximately CNY 130 million on March 31, 2025. The consideration consist of CNY 5.064 per ChemPartner PharmaTech Co.,Ltd. share. Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. on May 20, 2025.
공고 • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time.
공고 • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공고 • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
공고 • Nov 16ChemPartner PharmaTech Co.,Ltd. Approves the Election of DirectorsChemPartner PharmaTech Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 14 November 2024, during which the following proposal(s) was/were approved the election of Chen Wanglong as non-independent director and Zhang Xuemei as independent director.
공고 • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
Reported Earnings • Aug 30Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)Second quarter 2024 results: CN¥0.076 loss per share (down from CN¥0.011 profit in 2Q 2023). Revenue: CN¥230.6m (down 20% from 2Q 2023). Net loss: CN¥37.4m (down CN¥44.2m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.
공고 • Jun 29ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
공고 • Apr 28Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China Agenda: To consider 2023 work report of the board of directors; to consider 2023 annual accounts report; to consider 2023 annual report and its summary; to consider 2023 profit distribution plan; to consider Application for comprehensive credit line to banks and other financial institutions and provision of guarantee; to consider Shareholder return plan for the next three years from 2024 to 2026; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; to consider Change of the Company's business scope and amendments to the Company's articles of association; to consider 2023 work report of the supervisory committee; and to consider other business matters.
Reported Earnings • Apr 27First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)First quarter 2024 results: CN¥0.051 loss per share (improved from CN¥0.057 loss in 1Q 2023). Revenue: CN¥234.6m (down 13% from 1Q 2023). Net loss: CN¥25.5m (loss narrowed 11% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.
New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
공고 • Mar 30Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
공고 • Dec 30Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024
Reported Earnings • Oct 25Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)Third quarter 2023 results: CN¥0.048 loss per share (down from CN¥0.13 profit in 3Q 2022). Revenue: CN¥288.7m (down 16% from 3Q 2022). Net loss: CN¥19.4m (down 129% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.011 (down from CN¥1.90 in 2Q 2022). Revenue: CN¥288.8m (down 3.9% from 2Q 2022). Net income: CN¥6.79m (down 99% from 2Q 2022). Profit margin: 2.4% (down from 315% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years.
New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 58% over the past three years.
Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)First quarter 2023 results: CN¥0.057 loss per share (down from CN¥0.019 profit in 1Q 2022). Revenue: CN¥268.7m (down 31% from 1Q 2022). Net loss: CN¥28.6m (down 402% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Jiahui Qi is the most experienced director on the board, commencing their role in 2018. Independent Director Ji Guo Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2021). Revenue: CN¥345.3m (down 17% from 3Q 2021). Net income: CN¥66.8m (up CN¥57.1m from 3Q 2021). Profit margin: 19% (up from 2.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)Second quarter 2022 results: EPS: CN¥1.90 (up from CN¥0.007 in 2Q 2021). Revenue: CN¥300.6m (down 34% from 2Q 2021). Net income: CN¥947.1m (up CN¥943.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.019 (up from CN¥0.003 in 1Q 2021). Revenue: CN¥386.3m (flat on 1Q 2021). Net income: CN¥9.47m (up 480% from 1Q 2021). Profit margin: 2.5% (up from 0.4% in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Member of the Supervisory Board Hai Zhang was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to CN¥12.10, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 44x in the Biotechs industry in China. Total loss to shareholders of 22% over the past three years.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥455.7m (up 16% from 2Q 2020). Net income: CN¥3.51m (down 94% from 2Q 2020). Profit margin: 0.8% (down from 14% in 2Q 2020).
Valuation Update With 7 Day Price Move • May 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥16.39, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 41% over the past year.
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥389.7m (up 40% from 1Q 2020). Net income: CN¥1.63m (up CN¥15.8m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.
Is New 90 Day High Low • Mar 16New 90-day low: CN¥12.64The company is down 27% from a price of CN¥17.30 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Lagged the Biotechs industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: CN¥12.66The company is down 36% from its price of CN¥19.93 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥14.46, the stock is trading at a trailing P/E ratio of 51.2x, down from the previous P/E ratio of 60.5x. This compares to an average P/E of 63x in the Biotechs industry in China. Total returns to shareholders over the past year are 10%.
Is New 90 Day High Low • Dec 24New 90-day low: CN¥14.46The company is down 31% from its price of CN¥20.99 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.
Is New 90 Day High Low • Nov 12New 90-day low: CN¥18.29The company is down 4.0% from its price of CN¥19.06 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.18 per share.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 8.5% from the prior year. Total revenue was CN¥1.44b over the last 12 months, up 8.5% from the prior year.